Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Authors:
- 22 June 2017
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 471 (3) , 355-362
Abstract
The objective of this study was to validate the diagnostic and clinical role of four protein products of genes previously found to be differentially expressed in uterine low-grade endometrial stromal sarcoma (LG-ESS) compared to uterine leiomyosarcoma (LMS). Protein expression by immunohistochemistry of transgelin (TGLN), neuron navigator-2 (NAV2), fatty acid binding protein-3 (FABP3), and cyclin D2 (CCND2) was analyzed in 305 uterine sarcomas (231 LMS, 74 LG-ESS). Expression was analyzed for association with clinicopathologic parameters and survival. TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG-ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 expression was associated with shorter overall survival in patients with LMS (p = 0.037), whereas nuclear CCND2 expression in LG-ESS was significantly related to longer survival (p = 0.012) in univariate analysis. Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis (p = 0.023). In conclusion, TGLN, FABP3, NAV2, and nuclear CCND2 aid in differentiating LG-ESS from LMS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively.Keywords
Funding Information
- National Sarcoma Foundation at the Norwegian Radium Hospital (None)
This publication has 25 references indexed in Scilit:
- Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)Oncotarget, 2016
- Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathwayJournal of Experimental & Clinical Cancer Research, 2015
- Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something newJournal of Clinical Pathology, 2015
- Transgelin, a Novel Marker of Smooth Muscle Differentiation, Effectively Distinguishes Endometrial Stromal Tumors from Uterine Smooth Muscle Tumors2014
- Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumorsLaboratory Investigation, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- “Low-Grade Leiomyosarcoma” and Late-Recurring Smooth Muscle Tumors of the UterusAmerican Journal of Surgical Pathology, 2011
- Cyclin D as a therapeutic target in cancerNature Reviews Cancer, 2011
- Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patientsLaboratory Investigation, 2009
- Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosisThe Journal of Pathology, 1999